2 completed, 1 terminated. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow halofuginone: new trials by email Literature Review of halofuginone trials Research Report on halofuginone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02 HT-100 - Duchenne Muscular Dystrophy | Phase 2 | Terminated | Akashi Therapeutics | 10 | 2015-05-01 | 2019-03-12 |
| Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma halofuginone hydrobromide, placebo, laboratory biomarker analysis - AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 30 | 2003-05-01 | 2013-06-05 |
| Halofuginone Hydrobromide in Treating Patients With Progressive Advanced Solid Tumors halofuginone hydrobromide - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 25 | 2001-08-01 | 2012-07-24 |
AIDS-related Kaposi sarcoma (1) · Muscular Dystrophy, Duchenne (1) · Sarcoma, Kaposi (1)
Akashi Therapeutics (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · National Cancer Institute (NCI) (1)
United States (2) · Belgium (1) · Netherlands (1)
Diana M Escolar, MD (1) · Maja De Jonge, MD, PhD (1) · Susan Krown (1)
U01CA070019 (1)